Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 468 Active
• 1104 Finished

Grants per year

Search results

• Finished

  Research supplement for aberrant megakaryopoiesis in the myeloproliferative neoplasms

  Crispino, J. D.

  National Heart, Lung, and Blood Institute

  5/1/17 → 8/31/20

  Project: Research project

  • Megakaryocytes 100%
  • Primary Myelofibrosis 69%
  • Ribosomes 21%
  • Polycythemia 17%
  • Neoplasms 14%

• Reversing primary anti-PD-1 resistance with ipilimumab and nivolumab

  Sosman, J. A.

  University of California at Los Angeles, American Association for Cancer Research

  5/1/17 → 4/30/20

  Project: Research project

  • Ipilimumab 100%
  • Nivolumab 96%
  • Translational Medical Research 40%
  • Publications 29%
  • Medicine 26%

• Therapy Consortium Award

  Hussain, M.

  Prostate Cancer Foundation

  5/1/17 → 12/31/21

  Project: Research project

  • cancer 100%

• Prot #D081DC00007: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment w

  Hussain, M.

  Covance Inc., AstraZeneca Pharmaceuticals LP

  4/7/17 → 4/7/20

  Project: Research project

• VA IPA for Kazumi Ebine

  Munshi, H. G.

  Jesse Brown VA Medical Center

  4/1/17 → 7/30/18

  Project: Research project

• Prot #NU HM16B03: Neoadjuvant Phase II Study of Everolimus Plus Cisplatin in Triple Negative Breast Cancer Patients with Residual Disease After Standard Chemotherapy

  Cristofanilli, M.

  Methodist Hospital Research Institute, Novartis Pharmaceuticals Corporation

  3/30/17 → 3/30/20

  Project: Research project

• Prot #CA-170-101: A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas

  Sosman, J. A.

  INC Research, LLC, Curis, Inc.

  3/14/17 → 3/14/20

  Project: Research project

• Prot #CUDC-907-201: Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations

  Winter, J. N.

  PRA Health Sciences, Curis, Inc.

  3/3/17 → 3/3/20

  Project: Research project

• Prot #INCB 24360-203: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 (Epacadostat) in Combination With MEDI4736 (Durvalumab) in Subjects With Selected Advanced Solid Tumors

  Matsangou, M.

  inVentiv Health Clinical, Incyte Corporation

  3/1/17 → 3/1/20

  Project: Research project

• Prot #APL-B-021-13: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

  Pro, B.

  Pharma Mar, S.A. Sociedad Unipersonal

  2/28/17 → 2/28/20

  Project: Research project

• Prot #20100031: NU 16B09: A Phase II, Open label Study to evaluate Denosumab in patients with ER and/or PR-positive, HER2-negative Metastatic Breast Cancer (MBC) with bone metastases and detectable circulating tumor cells (CTCs)

  Jain, S.

  Amgen, Inc.

  2/23/17 → 2/23/20

  Project: Research project

• Prot #MK-3475-361: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma

  Morgans, A. K. & Carneiro Filho, B. A.

  DrugDev Inc., Merck Sharp & Dohme Corporation

  2/17/17 → 2/28/22

  Project: Research project

• Prot #1315.2: An Open-Label, Phase I/II Trial To Determine The Maximum Tolerated Dose And Investigate Safety, Pharmacokinetics And Efficacy Of BI 836858 In Combination With Decitabine In Patients With Acute Myeloid Leukemia

  Altman, J. K.

  Boehringer Ingelheim Pharmaceuticals, Inc.

  2/13/17 → 2/13/20

  Project: Research project

• Macrophage Modulation of Lung Fibrosis

  Perlman, H. R., Bagheri, N., Bharat, A., Bhorade, S. M., Budinger, G. S., Hinchcliff, M. E., Misharin, A. & Peter, M. E.

  National Heart, Lung, and Blood Institute

  2/1/17 → 7/31/21

  Project: Research project

  • Alveolar Macrophages 100%
  • Fibrosis 76%
  • Macrophages 76%
  • Systemic Scleroderma 73%
  • Monocytes 64%

• Prot #MK-3475-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).

  Singhal, S.

  Merck Sharp & Dohme Corporation

  1/26/17 → 1/26/20

  Project: Research project

• Novel safe GR-targeted therapy for hematological malignancies

  Budunova, I. & Gordon, L. I.

  ILSI Health and Environmental Sciences Institute

  1/23/17 → 7/22/20

  Project: Research project

  • Glucocorticoid Receptors 100%
  • Hematologic Neoplasms 76%
  • Glucocorticoids 68%
  • Quality of Life 24%
  • Therapeutics 12%

• Subproject for Institution # SP0039920

  Peter, M. E.

  Indiana University-Purdue University Indianapolis, Ovarian Cancer Research Fund Alliance

  1/1/17 → 6/30/20

  Project: Research project

• Coleman Supportive Oncology Initiative (CSOI) - Cycle 2

  Kircher, S. M., Garcia, S. F. & Penedo, F. J.

  Coleman Foundation, Inc.

  1/1/17 → 8/31/18

  Project: Research project

  • Survivorship 100%
  • Patient Care 63%
  • Hospital Administration 59%
  • Financial Support 54%
  • Neoplasms 53%

• The Impact of Systemic Immunosuppression on Development of Brain Metastases In Patients with Non-Small Cell Lung Cancer

  Bloch, O., Bharat, A. & Mohindra, N. A.

  Northwestern Memorial Hospital

  1/1/17 → 12/31/17

  Project: Research project

  • Neoplasm Metastasis 100%
  • Immunosuppression 83%
  • Non-Small Cell Lung Carcinoma 82%
  • Brain 62%
  • Phenotype 57%

• C-097: Mininode: Injectable Reactor for Programmable Release of CAR T Cells to Solid Tumor

  Zhang, B.

  Searle Funds at The Chicago Community Trust

  1/1/17 → 12/31/21

  Project: Research project

• Epigenetic Vulnerabilities of Ovarian Cancer Stem Cells

  Matei, D. E. & Peter, M. E.

  Indiana University-Purdue University Indianapolis, Ovarian Cancer Research Fund Alliance

  1/1/17 → 6/30/20

  Project: Research project

• A-016: Development of a Novel Treatment for Ovarian Cancer Based on Toxic RNA

  Peter, M. E.

  Searle Funds at The Chicago Community Trust

  1/1/17 → 12/31/21

  Project: Research project

• Investigating the Immunotherapeutic Potential of Esophageal Cancer

  Wainwright, D. A. & Villaflor, V. M.

  Northwestern Memorial Hospital

  1/1/17 → 12/31/17

  Project: Research project

  • Esophageal Neoplasms 100%
  • Adenocarcinoma Of Esophagus 30%
  • Indoleamine-Pyrrole 2,3,-Dioxygenase 28%
  • Esophagectomy 24%
  • Neoadjuvant Therapy 24%

• IPA Agreement for Sima, Elena, FY17

  Matei, D. E.

  Jesse Brown VA Medical Center

  1/1/17 → 9/30/18

  Project: Research project

• Targeting CCR5 in Cancer Treatment

  Cristofanilli, M.

  Baruch S. Blumberg Institute, Dr. Ralph and Marian Falk Medical Research Trust

  1/1/17 → 11/29/18

  Project: Research project

  • Staining and Labeling 100%
  • Safety 90%
  • Preliminary Data 83%
  • Research Ethics Committees 81%
  • Clinical Trials 50%